Your browser doesn't support javascript.
loading
Fluorinated CRA13 analogues: Synthesis, in vitro evaluation, radiosynthesis, in silico and in vivo PET study.
Hassan, Ahmed H E; Park, Kyung Tae; Kim, Hye Jin; Lee, Hyo Jong; Kwon, Yeong Ho; Hwang, Ji Young; Jang, Choon-Gon; Chung, Jin Hwa; Park, Ki Duk; Lee, Sang Joo; Oh, Seung Jun; Lee, Yong Sup.
Afiliação
  • Hassan AHE; Medicinal Chemistry Laboratory, Department of Pharmacy, College of Pharmacy, Kyung Hee University, Seoul 02447, Republic of Korea; Department of Medicinal Chemistry, Faculty of Pharmacy, Mansoura University, Mansoura 35516, Egypt.
  • Park KT; Department of Life and Nanopharmaceutical Sciences, Kyung Hee University, Seoul 02447, Republic of Korea.
  • Kim HJ; Department of Life and Nanopharmaceutical Sciences, Kyung Hee University, Seoul 02447, Republic of Korea.
  • Lee HJ; Department of Life and Nanopharmaceutical Sciences, Kyung Hee University, Seoul 02447, Republic of Korea.
  • Kwon YH; Department of Life and Nanopharmaceutical Sciences, Kyung Hee University, Seoul 02447, Republic of Korea.
  • Hwang JY; College of Pharmacy, Sungkyunkwan University, Gyeonggi-do 16419, Republic of Korea.
  • Jang CG; College of Pharmacy, Sungkyunkwan University, Gyeonggi-do 16419, Republic of Korea.
  • Chung JH; PETcore, Bio-Imaging Center, Asan Institute for Life Science, Asan Medical Center, Seoul 05505, Republic of Korea.
  • Park KD; KHU-KIST Department of Converging Science and Technology, Kyung Hee University, Seoul 02447, Republic of Korea.
  • Lee SJ; PETcore, Bio-Imaging Center, Asan Institute for Life Science, Asan Medical Center, Seoul 05505, Republic of Korea.
  • Oh SJ; PETcore, Bio-Imaging Center, Asan Institute for Life Science, Asan Medical Center, Seoul 05505, Republic of Korea. Electronic address: sjoh@amc.seoul.kr.
  • Lee YS; Medicinal Chemistry Laboratory, Department of Pharmacy, College of Pharmacy, Kyung Hee University, Seoul 02447, Republic of Korea; Department of Life and Nanopharmaceutical Sciences, Kyung Hee University, Seoul 02447, Republic of Korea; KHU-KIST Department of Converging Science and Technology, Kyung
Bioorg Chem ; 99: 103834, 2020 06.
Article em En | MEDLINE | ID: mdl-32334193
ABSTRACT
Fluorine is a unique atom that imparts distinct properties to bioactive molecules upon incorporation. Herein, we prepare and study fluorinated derivatives of the nanomolar affine peripherally restricted dual CB1R/CB2R agonist; CRA13 and its analogs. Binding affinity evaluation relative to CRA13 proved the stronger binding affinity of compound 7c to CB1R and CB2R by 6.95 and 5.64 folds. Physicochemical properties evaluation proved compound 7c improved lipophilicity profile suggesting some enhanced BBB penetration relative to CRA13. Radiosynthesis of 18F-labeled compound 7c was conducted conveniently affording pure hot ligand. In vivo PET study investigation demonstrated efficient distribution of 18F-labeled compound 7c in peripheral tissues visualizing peripheral CB1R/CB2R generating time-activity-curves showing good standard uptake values. Despite enhanced BBB penetration and increased cannabinoid receptors binding affinity, low brain uptake of 7c was observed. In silico docking study explained the measured binding affinities of compounds 7a-d to CB1R. While most of previous efforts aimed to develop central cannabinoid PET imaging agents, 18F-labeled compound 7c might be a promising agent serving as a universal CB1R/CB2R PET imaging agents for diagnosis and therapy of various diseases correlated with peripheral cannabinoid system. It might also serve as a lead compound for development of PET imaging of peripheral and central cannabinoid systems.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Compostos Radiofarmacêuticos / Receptor CB1 de Canabinoide / Receptor CB2 de Canabinoide / Tomografia por Emissão de Pósitrons / Naftalenos Limite: Humans Idioma: En Ano de publicação: 2020 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Compostos Radiofarmacêuticos / Receptor CB1 de Canabinoide / Receptor CB2 de Canabinoide / Tomografia por Emissão de Pósitrons / Naftalenos Limite: Humans Idioma: En Ano de publicação: 2020 Tipo de documento: Article